EN DE
Watch Evotec SE for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Evotec SE (EVT) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Evotec SE stock €1.92, price €3.14, that is 38.9% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE · ISIN DE0005664809

ES Evotec SE logo Thin data Nov 7, 2026

Evotec SE

EVT · XETRA
Very expensive, weak quality

Our calculation puts a fair price 39% below what the stock costs today.

Low debt
Profit last quarter +191% vs. a year ago.
Quality 41/100
Expensive Growth (revenue 5y +9.5 %/yr in EUR)
Fair value €1.92 · Strongly overvalued
Loss-making · -25.2% net margin (TTM)
Negative free cash flow
Trails peers (2/11)
Narrow moat 10/100 · thin data
Thin data
Watch Evotec SE for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€45.35 €2.44 Fair Value €1.92 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range €2.44 – €45.35 · fair‑value band €1.43 – €2.87 · the €3.14 price screens above the €1.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Evotec in your weekly email

Every Wednesday you see whether Evotec is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics.

Show moreShow less

The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.

It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health.

The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore.

In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital.

Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019.

Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Stock analysis

Evotec SE (EVT) currently trades at €3.14, while our model-based Fair Value estimate is €1.92, 39% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: €1.43 (bear) to €2.87 (bull), the price of €3.14 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Evotec SE reported revenue of €788M in FY2025 versus €618M in FY2021, a compound +6.3%/yr. Reported net income was −€104M in FY2025.

Key figures

Market cap €559M Small · P/S ratio 0.78 · EPS (TTM) €−1.01 · Net margin −25.2% · Return on equity −25.1% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin −16.4% · Revenue (TTM) €718M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 52% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −39%, EVT screens richer than that median.

Fair Value models

Bear €1.43 Fair Value €1.92 Bull €2.87
Price €3.14 · Downside -38.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) €1.43 €1.92 €2.87 54
All 1 models by family
Asset-Based
NCAV (Graham) €1.43 €1.92 €2.87 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 4
Do the profits arrive as real cash?
Financial strength 54
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 22
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−1.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Start year 2020 (pandemic). Over 10 years: +20.0% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.7% (2020) → −17.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

EVT screens overvalued: fair value 39% below the price. Compare with Merck KGaA →

Compare Evotec SE with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks

Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −38.9% · Below median
Profitability
Return on assets −5.8% · Bottom 25%
Net margin (12 months) −25.2% · Bottom 25%
Operating margin (12 months) −16.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.6% · Below median
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.69× · Cheapest 25%
P/S (12 months) 0.78× · Cheapest 25%
PEG 1.43× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)3 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)79 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs EVT
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs EVT
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,947 +2% vs EVT
Haleon plc HLN $9.14 $8.61 −6% vs EVT
Merck KGaA MRK €149.20 €109.18 −27% vs EVT
Galderma Group GALD CHF 190.65 CHF 109.86 −42% vs EVT
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs EVT
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs EVT
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs EVT
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs EVT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Evotec SE: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Evotec SE Fair Value". https://www.fairvalue-calculator.com/stock/EVT.XETRA

Frequently asked questions

Is Evotec SE (EVT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of €1.92 versus a price of €3.14, about 39% lower (overvalued).
What is the fair value of EVT?
Our model-based fair value for Evotec SE is €1.92 (as of Nov 7, 2026), built from audited fundamentals. The current price: €3.14.
What is the quality score of EVT?
Evotec SE has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Evotec SE (EVT)?
Our model-based price target is the fair value of €1.92 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario €1.43, optimistic scenario €2.87. It is a calculation from audited fundamentals, not an analyst target.
What is the Evotec SE stock forecast for 2026?
Our models put fair value at €1.92, about 39% lower versus a price of €3.14 (overvalued). Cautious scenario €1.43, optimistic scenario €2.87. The calculation is refreshed regularly with new filings.
What is the revenue of Evotec SE (EVT)?
Evotec SE reported trailing-twelve-month revenue of about €718M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Evotec SE (EVT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Evotec SE it is €1.92 per share (as of Nov 7, 2026), against a price of €3.14. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Evotec SE stock overvalued or undervalued in 2026?
As of Nov 7, 2026, EVT trades above its calculated fair value: price €3.14, fair value €1.92, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EVT?
No. The price is what the market pays today (€3.14); the fair value is what the company's own numbers justify (€1.92). For Evotec SE the two are €1.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Evotec SE worth?
The market values Evotec SE at about €559M (market capitalisation, as of Nov 7, 2026). Per share that is €3.14; our models calculate a fair value of €1.92 per share.
What do the bullish and bearish scenarios say about EVT?
Our models span a range for Evotec SE: cautious scenario €1.43, base €1.92, optimistic €2.87 per share (as of Nov 7, 2026, price €3.14). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of EVT?
The PEG ratio of Evotec SE is 1.43 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Evotec SE (EVT)?
Balance-sheet figures for Evotec SE (as of Nov 7, 2026): return on equity −25.1%, debt of 0.42 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is EVT from its 52-week high?
Evotec SE trades at €3.14, about 52% below its 52-week high of €6.55 and 29% above the low of €2.44 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of €1.92 is for.
Which stocks are comparable to Evotec SE?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Evotec SE stock attractive at the current price?
The data as of Nov 7, 2026: price €3.14, calculated fair value €1.92 (−39%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EVT calculated?
We run Evotec SE through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of €1.92 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Evotec SE itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Evotec SE (EVT)?
The closing price on Nov 9, 2026 was €3.14. Our model-based fair value is €1.92, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Evotec SE right now?
The price sits above even our optimistic bull case (€2.87). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€1.43 to €2.87) leaves room in how you read the outcome.

Key figures of Evotec SE

How large is the market capitalisation of Evotec SE (EVT)?
The market capitalisation of Evotec SE is €559M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Evotec SE (EVT)?
The price-to-sales ratio of Evotec SE is 0.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Evotec SE (EVT)?
Earnings per share at Evotec SE are €−1.01. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Evotec SE (EVT)?
The net margin of Evotec SE is −25.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Evotec SE (EVT)?
The return on equity (ROE) of Evotec SE is −25.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Evotec SE (EVT)?
On an EBIT basis the return on assets of Evotec SE is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Evotec SE (EVT)?
The operating margin of Evotec SE is −16.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Evotec SE (EVT)?
Revenue at Evotec SE is growing +0.6% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Evotec SE (EVT)?
Earnings per share at Evotec SE are growing +191% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Evotec SE (EVT) generate?
The free cash flow of Evotec SE is −€82.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Evotec SE (EVT) carry?
The net debt of Evotec SE is €29.2M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Evotec SE in the live analysis

One click puts Evotec SE on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.